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ABSTRACT 
Objective: To develop coenzyme Q10 (co-Q10) nanostructured lipid carriers (NLCs) using stearic acid (SA) and various liquid lipids with different 
lipophilicity as well as highlights the use of in silico studies for predicting and elucidating the interaction of drug-lipid used as carries in NLCs, at the 
molecular level. 
Methods: The co-Q10 NLCs were prepared using SA as solid lipid and oleic acid (OA), isopropyl myristate (IPM), as well as isopropyl palmitate 
(IPP) as liquid lipids by the high shear homogenization method. Firstly, the formulas were optimized by the appropriate required HLB (rHLB). The 
optimized NLCs were characterized in the particle size, distribution of particle size, zeta potential, crystallinity behavior, Fourier transform infrared 
(FT-IR) spectra, morphology, entrapment efficiency (EE), drug loading (DL), and pH value. The interaction of drug-lipids in silico was studied using 
the AutoDock Vina program. 
Results: The co-Q10 NLCs using SA and the various liquid lipid possessed the mean particle size, polydispersity index (PDI), zeta potential, EE, DL, 
and pH values were 180 to 350 nm,<0.5,<-30 mV, 83 to 88%, 10 to 11%, and 5.0 to 5.6, respectively. The EE and DL of co-Q10 NLCs increased with 
decreasing in binding energy (∆G) in silico.  
Conclusion: The co-Q10 NLCs using SA as solid lipid and OA, IPM, as well as IPP as liquid lipids were developed successfully. Furthermore, in silico 
study by molecular docking is a potential approach in predicting and elucidating the interaction of drug-lipid in the development of NLCs formulation.  
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INTRODUCTION 
Co-Q10 is an antioxidant that can be used as a skin anti-aging. Co-
Q10 is lipophilic because it has 10 isoprene side chains. The 
chemical structure of co-Q10 is shown in fig. 1. Due to its lipophilic 
properties, the penetration of co-Q10 through the skin is low [1, 2]. 
This problem can be overcome using NLC. 
NLC is the second generation of the lipid nanoparticle delivery system. 
NLCs have lipid carriers consisting of a mixture of solid lipids and 
liquid lipids [3, 4]. The main components of NLC are lipids, surfactants, 
and water [5]. These components determine emulsion stability during 
the NLC production process. The required hydrophilic-lipophilic 
balance (rHLB) value of the lipid matrix should be matched to the HLB 












Fig. 1: Chemical structure of co-Q10, SA, OA, IPM, IPP 
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In the present study, Tween 80 (HLB=15) and Span 80 (HLB=4.3) [8] 
were used as a combination of surfactants, SA as a solid lipid, OA, 
IPM, and IPP as liquid lipids. The liquid lipids have different 
lipophilicity. The chemical structure of SA, OA, IPM, and IPP is shown 
in fig. 1. The co-Q10 NLCs were characterized in particle size, PDI, 
zeta potential, morphological, differential scanning calorimetry 
(DSC) thermogram, FT-IR spectra, EE, DL, and pH values. Evaluation 
in silico was also performed by molecular docking to predict and 
elucidate the interaction between co-Q10 and the liquid lipids used. 
The interaction between co-Q10 and liquid lipids was analyzed 
through ΔG. Low ∆G shows stable interactions between molecules 
[9] and it can affect EE and DL [10]. 
MATERIALS AND METHODS 
Materials 
Co-Q10 was purchased from Kangcare Bioindustry Co., Ltd. (Nanjing, 
China). SA, IPP, IPM, propylene glycol, Tween 80 were purchased 
from Bratachem (Surabaya, Indonesia). OA, Span 80, 
phenoxyethanol were purchased from Universal Pharma Chemical 
(Surabaya, Indonesia). Sodium dihydrogen phosphate p. a., disodium 
hydrogen phosphate p. a., ethanol 96% p. a. were purchased from E. 
Merck (Darmstadt, Germany). All materials used in the study have a 
pharmaceutical-grade unless otherwise stated. 
Methods 
Molecular docking  
The chemical structure and International Union of Pure and Applied 
Chemistry (IUPAC) name of co-Q10, OA, IPM, and IPP were confirmed 
using PubChem®. The three dimensional (3D) chemical structure of 
co-Q10 and liquid lipids were obtained using ChemOffice Pro 2016, 
and the energy minimization process was carried out using the same 
program. The files were saved in the cdx file format. Files with the cdx 
format were converted to file. pdb using the Discovery Studio 
Visualizer (DSV). File. pdb from DSV becomes file. pdbqt on AutoDock 
Tools (ADT). Molecular docking of co-Q10 and various lipids were run 
using AutoDock Tools 1.5.6 and AutoDock Vina. Spasing (Armstrong) 
was selected 1, the position and size of the grid box were arranged so 
that all the structure of co-Q10 and liquid lipids were in the grid box, 
as shown in table 1. The number of molecular docking processes was 
10 times. Visualization of docking results used DSV and ADT. 
  
Table 1: Position and size of the grid box in the molecular docking process 
Molecule Grid box 
Parameter Center Size 
Co-Q10 and OA X -1.54 126 
Y -2.404 126 
Z -0.489 124 
Co-Q10 and IPM X -1.54 126 
Y -2.404 104 
Z -0.489 110 
Co-Q10 and IPP X -1.54 98 
Y -2.404 126 
Z -0.489 106 
 
Formulation of co-Q10 NLCs 
SA was put into liquid lipids then it was melted at 80 °C and stirred 
until homogeneous for about 1 min at 3400 rpm with ultra turrax. 
Co-Q10 was added to the lipid mixture and stirred until it dissolved 
for about 2 min. Separately, Span 80 and tween 80 were heated to 
80 °C, added sequentially, and stirred until homogeneous for about 1 
min. The phosphate buffer and propylene glycol were heated to 80 
°C separately from the lipid phase. The mixture was added slowly to 
the lipid phase and stirred until it was homogeneous for about 1 
min. After that, the mixture was stirred at 24 000 rpm for 3 min. 
After 3 min the stirring speed was changed to 3400 rpm. 
Phenoxyethanol was added to the mixture at 40 °C and stirred 
continuously until room temperature. 
Optimization of co-Q10 NLCs formula  
Several formulas with different rHLB and different concentrations of 
the lipid matrix were evaluated to obtain physically stable NLCs. The 
physical stability of the NLCs was evaluated for 10 d at room 
temperature by visual examination. The stable NLCs did not show 
phase separation or breaking. The formulations to determine the 
rHLB and the concentrations of the lipid matrix of the co-Q10 NLCs 
were presented in table 2. 
 
Table 2: The Formulations for rHLB determination of the co-Q10 NLC (concentration of materials given in %) 
Material Surfactant (10%)  Surfactant (20%)  
Lipid (8%) Lipid (10%)  Lipid (8%)  
rHLB 13 rHLB 14 rHLB 14 rHLB 13 rHLB 14 
F1 F2 F3 F4 F5 F6 F7 F8 
Co-Q10 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
SA 5.6 5.6 5.6 7 7 5.6 5.6 5.6 
OA  - - - - - 2.4  - 
IPM 2.4 - - - - - 2.4 - 
IPP - 2.4 2.4 3 3 2.4 2.4 2.4 
Tween 80 8.1 8.1 9.0 9.0 16.2 18 18 18 
Span 80 1.9 1.9 1.0 1.0 3.8 2 2 2 
Propylene glycol 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 
Phenoxyethanol 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 
Phosphate buffer pH 5.5 up to 100 100 100 100 100 100 100 100 
 
Physicochemical characterization of the co-Q10 NLCs  
Particle size, polydispersity index, and zeta potential 
The particle size, polydispersity index, and zeta potential were 
measured by the dynamic light scattering (DLS) method using the 
nanoparticle analyzer (Nanotrac Wave, Microtrac W3717). 
Morphology of the co-Q10 NLCs  
The morphology of the co-Q10 NLCs was performed using scanning 
electron microscopy (SEM, ZEISS). The samples were applied to an 
object-glass and dried at 40-50 °C using a hot plate. After that, the 
samples were coated with gold and observed by SEM with 
magnifications of 10 000x and 25 000x. 
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Differential scanning calorimetry (DSC) 
DSC was used to determine the melting temperature and 
crystallinity of co-Q10, SA, and co-Q10 NLCs. The weighted sample 
(4 mg) was put into an aluminum pan and heated from 30 to 100 °C 
in a calorimeter (DSC model 1/500, Mettler Toledo). The heating 
rate of the calorimeter was 10 °C/min. The percentage of 
crystallinity index (CI) is measured by the following equation [6]: 
CI (%) = ∆H NLC coenzyme Q10
∆ H lipid matrix X concentration lipid phase
 x100-----(1) 
Where ∆H co-Q10 NLC and ∆H lipid matrix are the melting enthalpy 
(J/g) of the co-Q10 NLC and solid lipid (SA), respectively. 
Fourier transform infrared (FT-IR) 
FT-IR spectra of the samples were obtained using an FT-IR 
spectrophotometer (Jasco FT-IR 5300). The samples were added to KBr 
powder and compressed with a hydraulic press to obtain a transparent 
plate. The plate was scanned at wavelengths of 400-4000 cm-1. 
Entrapment efficiency (EE) and drug loading (DL) 
The EE of co-Q10 NLC was obtained by indirect methods. The 
untrapped Co-Q10 in NLC was obtained through the centrifugation 
method. The co-Q10 NLC was diluted with aqua dem quantitatively 
and put into Amicon® Ultra-15 tubes with 30 kDa molecular weight 
cut-offs (Merck Millipore) then centrifuged at 10 000 rpm for 30 
min. The absorbance of the filtrate was measured using a UV 
spectrophotometer at a wavelength of 275 nm [11]. 
EE is calculated using the following equation:  
EE (%) = (Ca−Cb)
Ca
 x 100-----(2) 
DL is calculated using the following equation 
DL (%) = Da−Db
DL  
x 100-----(3) 
Where Ca is the initial concentration of co-Q10 in NLC, Cb is the 
concentration of free co-Q10 in the filtrate, Da is the initial amount 
of co-Q10 in NLC, Db is the amount of free co-Q10 in the filtrate, DL 
is the amount of lipid in co-Q10 NLC. 
The pH value 
The pH values of the co-Q10 NLCs were evaluated using a calibrated 
pH meter. 
Data analysis 
Differences in the particle size, EE, DL, and pH value of the co-Q10 
NLCs were analyzed using one-way ANOVA statistical methods, 
which were followed by Tuckey Honestly test to see different data 
pairs. The results were considered to be a statistically significant 
difference at p-value<0.05. The correlation between in silico and in 
vitro study was analyzed by regression analysis. There is a 
significant relationship if the correlation coefficient (r)>0.9877. 
RESULTS AND DISCUSSION 
Molecular docking 
The results of molecular docking between co-Q10 and liquid lipids 
showed that the ∆G  in silico of co-Q10-IPP was the lowest. This 
shows that IPP had the highest affinity for co-Q10. IPP has the 
longest hydrocarbon chain so that the lipophilicity is highest [12]. 
Due to the highest lipophilicity leads to the affinity of IPP to co-Q10 
is highest. The ∆G  in silico of co-Q10-OA, co-Q10-IPM, and co-Q10-
IPP were-4.9,-5.7, and-6.5 kcal/mol, respectively, as presented in 
table 5.2. A negative ∆G value indicates that the inte raction between 
fatty acid molecules and the co-Q10 can occur spontaneously [13, 
14].  
The 3D visualization of molecular docking using DSV showed that 
there were the hydrophobic bonds in co-Q10-OA, co-Q10-IPM, and 
co-Q10-IPP, as shown in fig. 2. The C18 atom of OA forms 
hydrophobic bonds with the C58 and C59 atoms of co-Q10 with a 
distance of 3.72 and 4.09 Å, respectively. The C14 atom and C15 
atom of IPM form hydrophobic bonds with the C56 atom and the 
C51 atom of co-Q10 with a distance of 4.01 Å and 4.48 Å, 
respectively. The C18 atom of IPP forms a hydrophobic bond with 
the C51 atom of co-Q10 with a distance of 3.96 Å. The results of 
molecular docking in the previous study also showed the 
hydrophobic bond in co-Q10-docosahexaenoic acid (DHA) and co-
Q10-eicosapentaenoic acid (EPA). Docosahexaenoic acid and 
eicosapentaenoic acid are chemical content of fish oil, which was 
used as a carrier of the oleogel formulation [15]. 
Intermolecular interactions can be in the form of ionic, ion-dipole, 
and dipole-dipole bonds, hydrogen bonds, van der Waals bonds, and 
hydrophobic bonds [9]. The 3D visualization of co-Q10-OA, co-Q10-
IPM, and co-Q10-IPP using the DSV only show hydrophobic 
interactions. The van der Waals interaction could not be shown in 
the interaction of these molecules because of the limitations of the 
software used. The van der Waals interactions can occur in non-
polar molecules [14]. It is attractive forces between molecules or 
atoms that are not charged and are located close to a distance of±4-6 
Å. The van der Waals interaction occurs due to the polarity of the 
induced atoms. It is a weak interaction, but if a large amount can 
produce significant ∆G in the interactions between molecules [9]. 
Co-Q10, OA, IPM, and IPP are non-polar [12]. These molecules 
showed van der Waals interactions using ADT, as shown in fig. 3. 
 
 
Fig. 2: Docking of co-Q10 with OA (A), IPM (B), and IPP (C) using DSV show hydrophobic bonds 
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Table 3: The binding energies of co-Q10 with various liquid lipids by molecular docking 
Liquid lipids IUPAC name ∆G (kcal/mol) 
OA (C18H34O2) (~{Z})-octadec-9-enoic acid -4.9 
IPM (C17H34O2) Propan-2-yl tetradecanoate -5.7 
IPP (C19H38O2) Propan-2-yl hexadecanoate -6.5 
 
Optimization of co-Q10 NLCs formula 
The main components of NLC are solid lipids, liquid lipids, 
surfactants, and water [16]. These components are the factors that 
determine the formation of a stable emulsion during the NLC 
manufacturing process. The required HLB (rHLB) of matrix lipid and 
amount of surfactants are the factors that determining emulsion 
stability [6, 7, 17-19]. 
 
 
Fig. 3 Docking co-Q10 with OA (A), IPM (B), and IPP (C) using ADT show van der Waals interactions 
 
In this study, the surfactants were a combination of Tween 80 and 
span 80. The optimization of the formula used 10 and 20% 
surfactants, with rHLB values of 13 and 14. The lipid matrix 
concentrations were 8 and 10%. The stability of the co-Q10 NLCs 
was evaluated for 10 d at room temperature to select the optimal 
formula.  
The results of the stability test visually of co-Q10 NLC at room 
temperature for 10 d are shown in table 4. The co-Q10 NLC (F6), 
(F7), and (F8) were not breaking. The co-Q10 NLC (F6), (F7), and 
(F8) used an 8% lipid matrix with rHLB value 14, 20% surfactants as 
well as OA, IPM, and IPP as liquid lipids, respectively. Then the 
optimized NLCs were characterized physicochemically. 
 
Table 4: The physical stability by visual evaluation 
Formula Physical stability 
Co-Q10 NLC (F1) Breaking 
Co-Q10 NLC (F2) Breaking after 7 d 
Co-Q10 NLC (F3) Breaking after 10 d 
Co-Q10 NLC (F4) Breaking after 4 d 
Co-Q10 NLC (F5) Breaking after 10 d 
Co-Q10 NLC (F6) Not breaking 
Co-Q10 NLC (F7) Not breaking 
Co-Q10 NLC (F8) Not breaking 
 
Physicochemical characterization of the co-Q10 NLCs  
Particle size, polydispersity index, and zeta potential 
The particle size of the co-Q10 NLCs (F6) was largest, while the 
particle sizes of the co-Q10 NLCs (F7) and (F8) were not different, as 
shown in table 5. The particle size of transdermal delivery systems is 
smaller than 600 nm and the particle size of drug<300 nm is optimal 
for penetration through the skin [20]. 
The PDI of co-Q10 NLCs (F6), (F7), and (F8) were<0.5, as shown in 
table 5. This indicates that the particle size distribution of the co-
Q10 NLCs (F6), (F7), and (F8) were homogenous [21, 22]. 
The zeta potential of co-Q10 NLCs (F6), (F7), and (F8) were<-30 mV, 
as shown in table 5, that indicated the formulas have good stability. 
The negative zeta potential values of co-Q10 NLC (F6), (F7), and (F8) 
were caused by the carboxyl group of SA. The negative zeta potential 
of the nano lipid particle delivery system using SA as a lipid matrix 
was also obtained in the earlier studies [23-25]. 
 
Table 5: Particle size, PDI, and zeta potential of co-Q10 NLCs 
Formula Parameter 
Particle size (nm) PDI Zeta potential (mV) 
Co-Q10 NLC (F6) 356.0±28.8 0.3100±0.1000 -41.4±5.6 
Co-Q10 NLC (F7) 236.4±48.8 0.3167±0.0900 -46.8±12.3 
Co-Q10 NLC (F8) 184.2±16.3 0.1838±0.1110 -54.6±1.0 
mean±SD (n=3) 
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Morphology of the co-Q10 NLCs  
To obtain information about the morphology of the co-Q10 NLCs, 
SEM analysis was performed. The micrograph of the co-Q10 NLCs 
(F6), (F7), and (F8) illustrated spherical particles and relatively 
smooth surface as shown in fig. 4, 5, and 6. The sticky nature of the 
lipid and sample preparation process for SEM analysis were 
probably the causes of the presence of some aggregates [26]. 
 
 
Fig. 4: SEM image of co-Q10 NLC (F6) with magnification of (A) 10 000x and (B) 25 000x 
 
 
Fig. 5: SEM image of co-Q10 NLC (F7) with magnification of (A) 10 000x and (B) 25 000x 
 
 
Fig. 6: SEM image of co-Q10 NLC (F8) with magnification of (A) 10 000x and (B) 25 000x 
 
Table 6: Melting point, melting enthalpy (∆H), and (CI) 
Material Melting point ( °C) ∆H (J/g) CI (%) 
Co-Q10 51.63 -153.2 - 
SA 58.01 -190.12 100 
Co-Q10 NLC (F6) 46.44 -4.32 28.40 
Co-Q10 NLC (F7) 45.30 -5.47 35.96 
Co-Q10 NLC (F8) 45.16 -5.01 32.94 
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Fig. 7: DSC thermogram of co-Q10 (A), SA (B), co-Q10 NLC (F6) (C), co-Q10 NLC (F7) (D), and co-Q10 NLC (F8) (E) 
 
Differential scanning calorimetry (DSC) 
The crystalline or amorphous nature of the co-Q10 NLCs (F6), (F7), 
and (F8) were analyzed by DSC. The DSC thermograms, melting 
point, and enthalpy of coenzyme Q10, SA, co-Q10 NLC (F6), co-Q10 
NLC (F7), and co-Q10 NLC (F8) are presented in fig. 7 and table 6. 
The melting points of co-Q10, SA, co-Q10 NLC (F6), (7), and (8) 
showed endothermic peaks at 51.63, 58.01, 46.44, 45.30, and 45.16 
°C, respectively. 
The melting enthalpies of co-Q10, SA, co-Q10 NLCs (F6), (F7), and (F8) 
were-153.2,-190.12,-4.32,-5.47, and-5.01 J/g, respectively. The melting 
point and melting enthalpy of co-Q10 NLC (F6), (F7), and (F8) were 
decreased compared with the melting point and the melting enthalpy 
of co-Q10 and SA. It is due to co-Q10 that was presented in the 
amorphous phase and dispersed homogeneously into the lipid matrix. 
The CI was calculated by comparing the enthalpy of co-Q10 NLC 
with the enthalpy of SA (equation 1). Lipid crystallinity affects EE 
and DL [7, 27]. The CI of co-Q10 NLC (F6), (F7), and (F8) are 
presented in table 6. The CI of SA was 100%. The addition of liquid 
lipids in the formula causes the enthalpy of co-Q10 NLC (F6), (F7), 
and (F8) was decreased compared with the enthalpy of SA. So, the CI 
of co-Q10 NLC (F6), (F7), and (F8) were smaller than the CI of SA. A 
similar result was also obtained from an earlier study, that the CI of 
NLC was decreased compared with the CI of the lipid used (carnauba 
wax, Compritol 888 ATO, and beeswax with certain liquid lipids) 
[28]. This is due to liquid lipids decreases the orderedness of the 
solid lipid crystal structures [4]. 
Fourier transform infrared (FT-IR) 
The FT-IR spectra of co-Q10, co-Q10 NLCs, and the lipids in the 
region of 4000–400 cm–1 is shown in fig. 8 to fig 10. The FT-IR 
spectra of co-Q10 exhibit peaks at 2962.13, 1732.73, 1645.95, and 
1200.47 cm-1 for C-H stretching, C=O stretching, C=C stretching and 
C-O stretching, respectively. The FT-IR spectra of co-Q10 NLCs did 
not present new peaks if compared with the FT-IR spectra of co-Q10, 
and the lipids. It was due to there were no chemical interactions that 
lead to forming new functional groups in the co-Q10 NLC. Co-Q10 is 
only entrapped in the lipid matrix [29, 30]. This was also proved by 
DSC thermograms that indicated co-Q10 was entrapped in the lipid 
matrix. Due to nonpolar molecules, the possible interactions 
between co-Q10 and matrix lipids are hydrophobic and van der 
Waals [14]. The molecular docking studies of co-Q10 and the lipids 
used showed hydrophobic and van der Waals interactions. The 
hydrophobic and van der Waals interactions did not lead to forming 
new functional groups. 
 
 
Fig. 8: FT-IR Spectra of co-Q10 (A), OA (B), SA (C), and co-Q10 NLC (F6) (D) 
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Fig. 9: FT-IR spectra of co-Q10 (A), IPM (B), SA (C), and co-Q10 NLC (F7) (D) 
 
 
Fig. 10: FT-IR spectra of co-Q10 (A), IPP (B), SA (C), and co-Q10 NLC (F8) (D) 
 
Entrapment efficiency (EE) and drug loading (DL)  
The EE of the co-Q10 NLC (F6, (7) and (F8) were>80%, as shown 
in table 7. These were due to the addition of liquid lipids into the 
SA lead to order crystal structure became disordered. Disorders of 
the crystal structure leave enough space for the incorporation of 
drug molecules [27]. The EE and DL of co-Q10 NLC (F8) were the 
highest.
 
Table 7: EE and DL of co-Q10 NLCs 
Formula EE (%) DL (%) 
Co-Q10 NLC (F6) 82.840±0.791 10.355±0.099 
Co-Q10 NLC (F7) 84.225±2.119 10.528±0.265 
Co-Q10 NLC (F8) 87.799±2.181 10.975±0.273 
mean±SD (n=3) 
 
Table 8: The pH values of co-Q10 NLC (F6), (F7), and (F8) 
Formula pH 
Co-Q10 NLC (F6) 5.55±0.01 
Co-Q10 NLC (F7) 5.67±0.04 
Co-Q10 NLC (F8) 5.50±0.07 
mean±SD (n=3) 
 
The co-Q10 NLCs pH value  
The co-Q10 NLC (F6), (F7), and (F8) possessed pH values similar to 
the pH value of the skin. The skin pH value is 4-6.5 [31]. The pH 
values of co-Q10 NLC (F6), (F7), and (F8) were about 5. The pH 
values co-Q10 NLC (F6), (F7), and (F8) are presented in table 8. 
The correlation of the EE or DL in vitro and the ∆G in silico 
Besides the crystallinity of lipids, the EE and DL in NLC also depend 
on the nature of the drug and lipids. The nature of the drug and 
lipids affect the interaction between them. Co-Q10 is a lipophilic 
substance (log P=21) [1], so it has good interaction with lipids.  
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To evaluate the influencing of interactions drug-lipid on EE and DL, 
the regression analysis between EE or DL and ∆G in silico was 
performed. The correlation curve between EE or DL and the ∆G in 
silico is presented in fig. 11. 
  
 
Fig. 11: Correlation of ∆G in silico and EE (A) and DL (B) of co-Q10 NLCs 
 
Although the non-fitting correlations were observed between EE or 
DL of co-Q10 NLCs in vitro and ∆G in silico, the EE and DL of co-Q10 
NLCs increased with decreasing in ∆G in silico. Similar results were 
also obtained from a previous study, that studied the interactions 
between amorphous chitin nanoparticles with three different types 
of anti-cancer drugs such as curcumin, docetaxel, and 5-fluorouracil 
by the integration of in silico and in vitro studies [32]. 
CONCLUSION 
The development of co-Q10 NLCs using SA as solid lipid and OA, IPM, 
and IPP as liquid lipids were prepared successfully using the 
appropriate rHLB. The NLCs possessed the mean particle size, PDI, 
zeta potential were about 180-350 nm,<0.5,<-0.3 mV, respectively. 
The NLCs particles were spherical. The pH values of the co-Q10 NLCs 
met the skin pH. Co-Q10 was entrapped and dissolved in the lipid 
matrix, it was indicated from the FT-IR spectra and supported by in 
silico studies. The molecular docking exhibited hydrophobic bonds and 
van der Waals interaction between molecule co-Q10 and the lipids. 
The DSC studies showed that the crystallinity index of co-Q10 NLCs 
was smaller than SA, so it influenced the EE and DL of the co-Q10 
NLCs. The EE of the co-Q10 NLCs 83 to 88% and DL10 to 11%. The EE 
and DL of the co-Q10 NLCs increased with a decrease in ∆G in silico. So 
in silico study is a potential approach in predicting and elucidating the 
interaction of drug-lipid in the development of NLCs.  
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